IFNA1 and neoplasm: In addition to genetic variation, deficiencies in antigen presentation methods, T-cell receptor (TCR) signalling, interferon (IFN) signalling pathways, and expression of the MHC class I protein has been lost or mutated, along with tumour antigens (43, 44), which will impair the immune surveillance mechanism in the tumor microenvironment.